Generic Ziagen Availability

Ziagen is a brand name of abacavir, approved by the FDA in the following formulation(s):

ZIAGEN (abacavir sulfate - solution;oral)

  • Manufacturer: VIIV HLTHCARE
    Approval date: December 17, 1998
    Strength(s): EQ 20MG BASE/ML [RLD]

ZIAGEN (abacavir sulfate - tablet;oral)

  • Manufacturer: VIIV HLTHCARE
    Approval date: December 17, 1998
    Strength(s): EQ 300MG BASE [RLD] [AB]

Has a generic version of Ziagen been approved?

A generic version of Ziagen has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ziagen and have been approved by the FDA:

abacavir sulfate tablet;oral

  • Manufacturer: APOTEX INC
    Approval date: December 17, 2012
    Strength(s): EQ 300MG BASE [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: December 17, 2012
    Strength(s): EQ 300MG BASE [AB]
  • Manufacturer: HETERO LABS LTD III
    Approval date: September 13, 2013
    Strength(s): EQ 300MG BASE [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: June 18, 2012
    Strength(s): EQ 300MG BASE [AB]

Note: No generic formulation of the following product is available.

  • abacavir sulfate - solution;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ziagen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Carbocyclic nucleoside hemisulfate and its use in treating viral infections
    Patent 6,294,540
    Issued: September 25, 2001
    Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
    Assignee(s): Glaxo Wellcome Inc.
    The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
    Patent expiration dates:
    • May 14, 2018
      ✓ 
      Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 14, 2018
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical compositions
    Patent 6,641,843
    Issued: November 4, 2003
    Inventor(s): Nikki Thoennes; Brooks
    Assignee(s): SmithKline Beecham Corporation
    The present invention relates to pharmaceutical compostions of (1S,4R)-cis-4-[2-amino-6-cyclopropylamino}-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89).
    Patent expiration dates:
    • February 4, 2019
      ✓ 
      Drug product
    • August 4, 2019
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web5)